Cell therapy (CAR-NK) · Kills target cells, directed at CD19 · developed by Fate Therapeutics
FT596 is an allogeneic, iPSC-derived CAR-NK cell product engineered to express an anti-CD19 chimeric antigen receptor, a high-affinity non-cleavable CD16 Fc receptor, and an IL-15/IL-15 receptor alpha fusion. It recognizes and kills CD19-expressing tumor cells and can enhance antibody-dependent cellular cytotoxicity with co-administered monoclonal antibodies. It is studied in B-cell lymphoma and chronic lymphocytic leukemia.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT04245722 | Phase 1 | Lymphoma, B-Cell | Terminated | FATE |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Chronic Lymphocytic LeukemiaLymphoma, B-Cell
Updated Nov 15, 2026. Something wrong or missing? Report it on the FATE page.
See FATE's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
FATE catalysts and pipeline →